Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Oral L-carnitine Supplement on Lipid Profile, Anemia, and Quality of Life of Patients

This study has been completed.
Information provided by:
Isfahan University of Medical Sciences Identifier:
First received: January 18, 2011
Last updated: NA
Last verified: August 2009
History: No changes posted
The purpose of this study is to determine Effect of oral L-carnitine supplement on lipid profile, anemia, and quality of life.

Condition Intervention Phase
Complication of Hemodialysis
Drug: L-carnitine
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Study of Treatment of Dyslipidemia for Hemodialysis

Resource links provided by NLM:

Further study details as provided by Isfahan University of Medical Sciences:

Primary Outcome Measures:
  • lipid profile [ Time Frame: at sixteen weeks after admission ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • anemia [ Time Frame: at sixteen weeks after admission ] [ Designated as safety issue: Yes ]
  • quality of life [ Time Frame: at sixteen weeks after admission ] [ Designated as safety issue: Yes ]

Enrollment: 54
Study Start Date: August 2009
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
it is as like as L-carnitine in shape
Drug: placebo
500 mg,twice daily, 16 weeks.
it is kind of supplement
Drug: L-carnitine
500 mg,twice daily, 16 weeks

Detailed Description:
In patients under maintenance hemodialysis several factors reduce the body stored carnitine which in turn affected dyslipidemia, anemia, and general health in these patients. The investigators evaluated the effect of oral L-carnitine supplementation on lipid profiles, anemia, and quality of life in hemodialysis patients.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

being in the age range of 18-75 having the history of at least 12 weeks of hemodialysis and at least three times a week and each session almost for four hours having serum triglyceride or total cholesterol concentration >200 mg/dl or serum HDL concentration >40 mg/dl in the beginning of the study.

Exclusion Criteria:

taking carnitine supplement or the drug that interact with carnation lowering the seizure threshold in the last month being affected by liver function abnormalities, hypothyroidism, chronic infectious diseases (such as hepatitis), inflammatory diseases, CNS mass having the history of seizure.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01278693

Iran, Islamic Republic of
Noor university hospital
Isfahan, Iran, Islamic Republic of
Sponsors and Collaborators
Isfahan University of Medical Sciences
Study Chair: Mahnaz Moradi, MD MD,research comittee
  More Information

Responsible Party: Dr. Alireza Yousefy, Associate Professor of Medical Education, Isfahan University of Medical Sciences Identifier: NCT01278693     History of Changes
Other Study ID Numbers: ASD-1213-11 
Study First Received: January 18, 2011
Last Updated: January 18, 2011
Health Authority: Iran: Ministry of Health

Keywords provided by Isfahan University of Medical Sciences:
Renal failure, hemodialysis, dyslipidemia, L-carnitine. processed this record on October 21, 2016